Back to results
US 2008/0075723 A1Published application
Endotheliase 2 ligands
AssigneeDyax Corp., a Massachusetts corporation
InventorsAndrew NIXON, Edwin MADISON
Life of this patent
Estimating the term…
Abstract
Proteins that bind to ET2, such as immunoglobulins that inhibit ET2 with high affinity and selectivity, are provided. The ET2 binding proteins can be used to treat a variety of disorders, including angiogenesis-associated disorders.
Claims15
An isolated protein comprising a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein
- (1) the first and second immunoglobulin variable domain sequences form an antigen binding site that specifically binds to human Endotheliase-2 (ET2);
- and
- (2) the protein has one or more of the following characteristics:
- (a) the protein inhibits ET2 with an inhibition constant (Ki) of less than 300 nM;
- (b) the HC immunoglobulin variable domain sequence comprises one or more CDRs that are at least 85%, identical to a CDR of a HC variable domain of A10, G3, A6, A7, C8, H9, G10-R2, F3-R2, C6-R2, A4-R3, C1-R3, A2, B5, D2, D5, F8, H10, or C9;
- (c) the LC immunoglobulin variable domain sequence comprises one or more CDRs that are at least 85% identical to a CDR of a LC variable domain of A10, G3, A6, A7, C8, H9, G10-R2, F3-R2, C6-R2, A4-R3, C1-R3, A2, B5, D2, D5, F8, H10, or C9;
- (d) the LC immunoglobulin variable domain sequence is at least 85% identical to a LC variable domain of A10, G3, A6, A7, C8, H9, G10-R2, F3-R2, C6-R2, A4-R3, C1-R3, A2, B5, D2, D5, F8, H10, or C9;
- (e) the HC immunoglobulin variable domain sequence is at least 85% identical to a HC variable domain of A10, G3, A6, A7, C8, H9, G10-R2, F3-R2, C6-R2, A4-R3, C1-R3, A2, B5, D2, D5, F8, H10, or C9;
- and
- (f) the protein binds an epitope that overlaps with an epitope bound by A10, G3, A6, A7, C8, H9, G10-R2, F3-R2, C6-R2, A4-R3, C1-R3, A2, B5, D2, D5, F8, H10, or C9.
7 more elements
Dependencies are inferred from the claim text.